menu search

INBX / Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fast Track designation from the FDA for the treatment of emphysema. Read More
Posted: Aug 17 2023, 16:41
Author Name: Seeking Alpha
Views: 111016

INBX News  

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

By Seeking Alpha
August 17, 2023

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatme more_horizontal

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

By Zacks Investment Research
May 4, 2023

Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate rev more_horizontal

Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
March 6, 2023

Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers more_horizontal

Inhibrx Announces Participation in Upcoming Investor Conference

By PRNewsWire
November 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of the more_horizontal

Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 8, 2022

Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold c more_horizontal

Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

By Zacks Investment Research
May 3, 2022

Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate rev more_horizontal


Search within

Pages Search Results: